QURE  valuation analysis

Name: uniQure N.V
Description: uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 02, 2022
Market cap: $657.98M (1314th)
Sales(TTM): $525.34M (1225th)
Earnings(TTM): $324.47M (646th)

FFER: 0.15*
Actual price: $14.12
* Earnings were reported Jul 25, 2022 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2022-05-25
Price & Estimates
Sales & Earnings history (TTM)
  • uniQure N.V's earnings increased from -$138.58M to $324.47M in the last year.
  • uniQure N.V's sales grew by 1287.4% ($37.86M to $525.34M) over one year against a market average growth of 29.0%.
  • uniQure N.V's operating income increased from -$135.42M to $301.00M in the last year.
Earnings / MarketCap
uniQure N.V
"Biotechnology" industry
Sales / MarketCap
uniQure N.V
"Biotechnology" industry
Book / MarketCap
uniQure N.V
"Biotechnology" industry
Equity / Assets
uniQure N.V
"Biotechnology" industry